Literature DB >> 12519306

Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism.

Eleanor J Cheadle, Peter J Selby, Andrew M Jackson.   

Abstract

Mycobacteria are potent adjuvants, can survive intracellularly and have been safely used for many years as vaccines against tuberculosis and leprosy. They are thus important potential vectors for recombinant vaccines. Many of their adjuvant properties are mediated following phagocytosis by dendritic cells (DC), which are in turn critical for priming naïve T cells. Although the maturation of DC in response to mycobacteria, such as Mycobacterium bovis bacillus Calmette-Guérin (BCG), is well described the subsequent responses of autologous T cells to mycobacterium-infected DC remains uncharacterized. In our experiments DC infected with BCG expressed more co-stimulatory molecules than tumour-necrosis factor-alpha (TNF-alpha) -treated DC and stimulated more potent mixed leucocyte reactions. When autologous T cells were co-cultured with BCG-exposed DC they became highly activated, as determined by display of CD25, CD54 and CD71 on both CD4+ and CD8+ cells. In contrast, the response of T cells to TNF-alpha-matured DC was significantly less. Cytokine production from T cells cultured with BCG-exposed DC was enhanced with elevated secretion of interleukin-2 (IL-2), IL-10 and interferon-gamma (IFN-gamma) and was produced by both CD4+ and CD8+ lymphocytes as determined by intracellular staining. In particular, IFN-gamma secretion was increased from 50 pg/ml to 25 000 pg/ml and IL-10 secretion increased from 20 pg/ml to 300 pg/ml in BCG-exposed DC co-cultures. Blocking antibodies to B7.1 and B7.2 or IL-12 significantly reduced the secretion of IFN-gamma and reductions were also seen in the expression of CD25 and CD71 by CD4+ cells. These data demonstrate that mycobacterially infected DC are particularly potent activators of autologous T cells compared to TNF-alpha-exposed DC and that the resultant T cells are functionally superior.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519306      PMCID: PMC1782863          DOI: 10.1046/j.1365-2567.2003.01543.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

Review 1.  Immune responses to intracellular bacteria.

Authors:  B Raupach; S H Kaufmann
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

2.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

3.  The response of human dendritic cells to recombinant adenovirus, recombinant Mycobacterium bovis Bacillus Calmette Guerin and biolistic methods of antigen delivery: different induction of contact-dependant and soluble signals.

Authors:  S G Smith; P M Patel; P J Selby; A M Jackson
Journal:  Immunol Lett       Date:  2001-03-01       Impact factor: 3.685

4.  Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity.

Authors:  Xinan Jiao; Richard Lo-Man; Pierre Guermonprez; Laurence Fiette; Edith Dériaud; Sophie Burgaud; Brigitte Gicquel; Nathalie Winter; Claude Leclerc
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

5.  Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines.

Authors:  A S Mustafa; F A Shaban; A T Abal; R Al-Attiyah; H G Wiker; K E Lundin; F Oftung; K Huygen
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response.

Authors:  E Giacomini; E Iona; L Ferroni; M Miettinen; L Fattorini; G Orefici; I Julkunen; E M Coccia
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.

Authors:  F Granucci; C Vizzardelli; N Pavelka; S Feau; M Persico; E Virzi; M Rescigno; G Moro; P Ricciardi-Castagnoli
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

8.  Dendritic cells induce CD4+ and CD8+ T-cell responses to Mycobacterium bovis and M. avium antigens in Bacille Calmette Guérin vaccinated and nonvaccinated cattle.

Authors:  J C Hope; L S Kwong; P Sopp; R A Collins; C J Howard
Journal:  Scand J Immunol       Date:  2000-09       Impact factor: 3.487

9.  Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.

Authors:  R Lau; F Wang; G Jeffery; V Marty; J Kuniyoshi; E Bade; M E Ryback; J Weber
Journal:  J Immunother       Date:  2001 Jan-Feb       Impact factor: 4.456

10.  Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope.

Authors:  C G Feng; C Demangel; A T Kamath; M Macdonald; W J Britton
Journal:  Int Immunol       Date:  2001-04       Impact factor: 4.823

View more
  8 in total

1.  Murine Flt3 ligand-generated plasmacytoid and conventional dendritic cells display functional differentiation in activation, inflammation, and antigen presentation during BCG infection in vitro.

Authors:  Chuang Meng; Xiaoyan Wang; Zhengzhong Xu; Maozhi Hu; Jiaying Liu; Zhiming Pan; Xiang Chen; Xinan Jiao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-08-05       Impact factor: 2.416

2.  BCG stimulated dendritic cells induce an interleukin-10 producing T-cell population with no T helper 1 or T helper 2 bias in vitro.

Authors:  Jeppe Madura Larsen; Christine Stabell Benn; Yvonne Fillie; Desiree van der Kleij; Peter Aaby; Maria Yazdanbakhsh
Journal:  Immunology       Date:  2007-03-20       Impact factor: 7.397

Review 3.  The role of dendritic cells in mycobacterium-induced granulomas.

Authors:  Heidi A Schreiber; Matyas Sandor
Journal:  Immunol Lett       Date:  2010-01-04       Impact factor: 3.685

4.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

5.  Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model.

Authors:  Heidi A Schreiber; Paul D Hulseberg; JangEun Lee; Jozsef Prechl; Peter Barta; Nora Szlavik; Jeffrey S Harding; Zsuzsanna Fabry; Matyas Sandor
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

6.  Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion.

Authors:  Elisabeth Billard; Jacques Dornand; Antoine Gross
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

7.  Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.

Authors:  Ricardo D Lardone; Alfred A Chan; Agnes F Lee; Leland J Foshag; Mark B Faries; Peter A Sieling; Delphine J Lee
Journal:  Front Immunol       Date:  2017-08-11       Impact factor: 7.561

8.  Early vaccination protects against childhood leukemia: A systematic review and meta-analysis.

Authors:  Mostafa Ebraheem Morra; Nguyen Dang Kien; Ahmed Elmaraezy; Omar Ayman M Abdelaziz; Ahmed Lotfy Elsayed; Oday Halhouli; Ahmed Mosaad Montasr; Tran Le-Huy Vu; Chau Ho; Amr Sayed Foly; Anh Phan Phi; Wessam Magdy Abdullah; Marina Mikhail; Elizabeth Milne; Kenji Hirayama; Nguyen Tien Huy
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.